Navigation Links
aTyr Pharma Honored with Red Herring 100 North America Award for Discovering and Developing Innovative Medicines Based on Physiocrine Biology
Date:6/17/2011

SAN DIEGO, June 17, 2011 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics company, announced today that Red Herring has named the company as a winner of the 2011 Red Herring 100 North America Award, a prestigious list honoring the year's most promising private companies. aTyr was recognized for its leadership and innovation in the discovery of Physiocrines and development of Physiocrine-based medicines. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases.

Dr. John Mendlein, executive chairman of aTyr Pharma, said, "Physiocrine protein pathways represent important new therapeutic intervention points for drug discovery.  aTyr is uncovering the role of Physiocrines from an ancient gene family in modulating human physiology and intervening in disease to develop life-changing medicines for patients with grave conditions."

Physiocrines are a recently elucidated class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in a variety of physiologic settings.   As either therapeutic proteins or as targets for antibodies, Physiocrines have the potential to address a wide range of diseases, including high unmet patient needs in blood, immune, and metabolism disorders.

"Choosing the companies with the strongest potential was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across North America to the Top 100 Winners. We believe aTyr Pharma embodies the vision, drive and innovation that define a successful entrepreneurial venture." 

Red Herring 100 North America list has become a mark of distinction for identifying promising new companies and entrepreneurs. The Red Herring 100 winners are evaluated on both quantitative and qualitative criteria, such as technology innovation, quality of management and execution of strategy into their respective industries. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Skype, YouTube and eBay would change the way we live and work.

"This award recognizes that the development of Physiocrine-based protein therapeutics is distinct from current protein therapeutic programs," said Dr. Jeff Watkins, CEO of aTyr Pharma. "aTyr possesses a unique opportunity to advance new therapeutic applications from novel mechanisms for the development of innovative, high-impact biologics."

About aTyr Pharma

aTyr Pharma develops biologic therapeutics based on Physiocrines and amino acyl tRNA synthetases and is currently focusing on developing products for hematologic and immune indications. aTyr has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. The company's lead program, Tmax, is in preclinical development. The privately held biotech was founded by Scripps Research Institute Professor Paul Schimmel, a leading amino acyl tRNA synthetase scientist, and is backed by leading life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
2. Florida Independent Drugstores Attack Mail-Service Pharmacies, Put Profits Ahead of Patients
3. Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
4. Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes
5. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
6. Ampio Pharmaceuticals Set to Join Russell 3000 Index
7. PDL BioPharma Completes Regular Quarterly Dividend Payment
8. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
9. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
10. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
11. Saint-Gobains New C-Flex® ULTRA Pump Tubing for Biopharmaceutical Applications Outperforms the Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):